André Albergaria

Principal

André Albergaria, Ph.D., Principal at Biovance Capital, brings over two decades of expertise in research and health innovation. He conducted his doctoral research at Imperial College London's School of Medicine, having authored over 35 publications in peer-reviewed journals. His unique blend of scientific knowledge and business acumen is bolstered by degrees in Molecular Oncology and Pharmaceutical Medicine, as well as postgraduate studies in BioBusiness from AMC University in Amsterdam.

André's experience spans academia, industry, and venture capital. As a Professor at the Medical Faculty of the University of Porto and former Member-Coordinator of i3S's Research and Innovation Unit, André was instrumental in fostering collaborations between global healthcare industry, clinicians, and researchers. His investment experience includes a successful tenure as an investment analyst at Portugal Ventures, where he managed three biotech companies, including Lymphact - the first successful exit in the Portuguese biotech landscape.

His expertise extends to European initiatives, collaborating with organizations like EATRIS and PerMed. His role as a health research expert is exemplified by his coordination of the Portuguese Agenda for Research and Innovation, Health, Clinical and Translational Research and co-authorship in the ICPerMed's vision paper.